Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 11298151
    Abstract: Device for accessing a pericardial space of a subject in need thereof, the device including a tubular member having an atraumatic distal end and a thread formed on, and at least partially around, the outer surface of the tubular member, proximally to the distal end; wherein the thread is configured to cut, puncture and/or penetrate a pericardium.
    Type: Grant
    Filed: June 17, 2018
    Date of Patent: April 12, 2022
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ran Eliaz, Yonathan Avraham Demma, Ziv Menshes, Or Hazan, Eva Abramov, Yaakov Nahmias, Amnon Buxboim, Yoav Kan-Tor, Yoav Mintz, Elchanan Fried
  • Patent number: 11273201
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 15, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • Patent number: 11261433
    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 1, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Ithai Waldhorn, Benjamin Eithan Reubinoff
  • Patent number: 11246912
    Abstract: The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 15, 2022
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Rinat Abramovitch, Esther Goldlist
  • Patent number: 11241147
    Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: February 8, 2022
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Itai Hayut, Elchanan Fried, Yaakov Nahmias, Tommy Weiss-Sadan, Ariel Shrem
  • Patent number: 11230696
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Orna Singer
  • Publication number: 20220010009
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: July 29, 2021
    Publication date: January 13, 2022
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Patent number: 11203784
    Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: December 21, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yuval Dor, Ruth Shemer, Benjamin Glaser
  • Patent number: 11161912
    Abstract: The present invention relates to heparanase-neutralizing monoclonal antibodies (m Abs), pharmaceutical composition comprising same, and use thereof for treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, diabetes and related complications. The present invention further provides combined therapies comprising the heparanase-neutralizing m Ab and an anti-cancer treatment such as chemotherapy or radiation, for treating a proliferative disease in a subject.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: November 2, 2021
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Israel Vlodavsky, Marina Weissmann, Neta Ilan, Gil Arvatz
  • Patent number: 11122972
    Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: September 21, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Jose Cohen, Vladimir Goldman, Yousef Nadim Farraj, Amnon Buxboim, Yoav Mintz, Elchanan Fried, Gahl Levy, Tsevi Beatus, Yoav Kan-Tor
  • Patent number: 11098116
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: August 24, 2021
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat Safadi
  • Patent number: 11091434
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: August 17, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
  • Patent number: 11053231
    Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 6, 2021
    Assignees: Hadasit Medical Research Services and Development Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Or Kakhlon, Miguel Enrique Weil, Leonardo Javier Solmesky
  • Patent number: 11034753
    Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 15, 2021
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Dan Deutsch, Amir Haze, Anat Blumenfeld
  • Patent number: 11035857
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 15, 2021
    Assignees: Hadasit Medical Research Services and Development Ltd., Cell Cure Neurosciences Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi
  • Publication number: 20210146101
    Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 20, 2021
    Applicants: Ramot at Tel-Aviv University Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer BARNEA, Omer DORON
  • Patent number: 10980866
    Abstract: Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 20, 2021
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Yaron Ilan
  • Patent number: 10940241
    Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 9, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Hadasit Medical Research Services and Development Ltd.
    Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
  • Patent number: 10933031
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 2, 2021
    Assignees: The Trustees of Columbia University in the City of New York, Hadasit Medical Research Services and Development Ltd., Ramot at Tel-Aviv University, Ltd.
    Inventors: Hasan Orhan Akman, Salvatore Dimauro, Or Kakhlon, Miguel Enrique Weil
  • Patent number: 10918677
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: February 16, 2021
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer Mandelboim, Gilad Benjamin Bachrach, Chamutal Gur, Vladimir Yutkin